UAB is participating in a Phase I/II trial of AMT 191, a one time gene therapy designed to enable patients with classic Fabry disease to produce their own missing enzyme, potentially reducing the need ...
A Japanese registry has identified a blind spot in the routine care of patients with chronic kidney disease (CKD). Serum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results